Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sheba Medical Center |
---|---|
Information provided by: | Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT00234689 |
Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD
Condition | Intervention |
---|---|
Obsessive Compulsive Disorder |
Drug: Naltrexone |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control, Crossover Assignment |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Chaim Sheba Medical Center | |
Ramat-Gan, Israel, 52621 |
Principal Investigator: | Joseph Zohar, MD | Tel Aviv University |
Study Chair: | Revital Amiaz, MD | Tel Aviv University |
Responsible Party: | Chaim Sheba Medical Center ( Prof. Joseph Zohar ) |
Study ID Numbers: | SHEBA-99-1897-JZ-CTIL |
Study First Received: | October 6, 2005 |
Last Updated: | January 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00234689 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Anxiety Disorders Mental Disorders Naltrexone Obsessive-Compulsive Disorder |
Sensory System Agents Therapeutic Uses Physiological Effects of Drugs Narcotic Antagonists |
Peripheral Nervous System Agents Central Nervous System Agents Pharmacologic Actions |